Repurposing the HCV NS3-4A protease drug boceprevir as COVID-19 therapeutics.

Oerlemans, Rick; Ruiz-Moreno, Angel Jonathan; Cong, Yingying; Dinesh Kumar, Nilima; Velasco-Velazquez, Marco A; Neochoritis, Constantinos G; Smith, Jolanda; Reggiori, Fulvio; Groves, Matthew R; Dömling, Alexander.

Afiliação

Oerlemans R; Department of Drug Design, University of Groningen The Netherlands a.s.s.domling@rug.nl.
Ruiz-Moreno AJ; Department of Drug Design, University of Groningen The Netherlands a.s.s.domling@rug.nl.
Cong Y; Departamento de Farmacología y Unidad Periférica de Investigación en Biomedicina Traslacional, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM) Ciudad de México Mexico.
Dinesh Kumar N; Programa de Doctorado en Ciencias Biomédicas, UNAM Ciudad de México Mexico.
Velasco-Velazquez MA; Department of Biomedical Sciences of Cells and Systems, University of Groningen, University Medical Center Groningen The Netherlands.
Neochoritis CG; Department of Biomedical Sciences of Cells and Systems, University of Groningen, University Medical Center Groningen The Netherlands.
Smith J; Department of Medical Microbiology and Infection Prevention, University of Groningen, University Medical Center Groningen Groningen 9700 RB The Netherlands.
Reggiori F; Departamento de Farmacología y Unidad Periférica de Investigación en Biomedicina Traslacional, Facultad de Medicina, Universidad Nacional Autónoma de México (UNAM) Ciudad de México Mexico.
Groves MR; Programa de Doctorado en Ciencias Biomédicas, UNAM Ciudad de México Mexico.
Dömling A; Telesis Pharma Groningen The Netherlands.

RSC Med Chem ; 12(3): 370-379, 2020 Dec 21.

Article em En | MEDLINE | ID: mdl-34041486

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2020 Tipo de documento: Article